Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C5H12N2O2.C4H7NO4 |
Molecular Weight | 265.2637 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NCCC[C@H](N)C(O)=O.N[C@@H](CC(O)=O)C(O)=O
InChI
InChIKey=IXUZXIMQZIMPSQ-ZBRNBAAYSA-N
InChI=1S/C5H12N2O2.C4H7NO4/c6-3-1-2-4(7)5(8)9;5-2(4(8)9)1-3(6)7/h4H,1-3,6-7H2,(H,8,9);2H,1,5H2,(H,6,7)(H,8,9)/t4-;2-/m00/s1
DescriptionSources: http://www.hmdb.ca/metabolites/HMDB00214Curator's Comment: description was created based on several sources, including
https://www.drugbank.ca/drugs/DB00129
Sources: http://www.hmdb.ca/metabolites/HMDB00214
Curator's Comment: description was created based on several sources, including
https://www.drugbank.ca/drugs/DB00129
Ornithine is an amino acid produced in the urea cycle by the splitting off of urea from arginine. It is a central part of the urea cycle, which allows for the disposal of excess nitrogen. Ornithine is also a precursor of citrulline and arginine. Arginine stimulates the pituitary release of growth hormone. Burns or other injuries affect the state of arginine in tissues throughout the body. As de novo synthesis of arginine during these conditions is usually not sufficient for normal immune function, nor for normal protein synthesis, ornithine may have immunomodulatory and wound-healing activities under these conditions (by virtue of its metabolism to arginine).
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22053755
Curator's Comment: Known to be CNS active in mouse. Human data not available.
Originator
Sources: https://doi.org/10.1515/bchm2.1932.210.1-2.33
Curator's Comment: Krebs, H.A. and Henseleit, K. Z. Physiol. Chem. 1932; 210: 33-66
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Q5T6X5 Gene ID: 222545.0 Gene Symbol: GPRC6A Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/15576628 |
112.0 µM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | L-Ornithine Approved UseUsed for nutritional supplementation, also for treating dietary shortage or imbalance. |
PubMed
Title | Date | PubMed |
---|---|---|
[Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome]. | 2001 |
|
Cancer chemopreventive activities of S-3-1, a synthetic derivative of danshinone. | 2001 |
|
Diagnosis of Japanese patients with HHH syndrome by molecular genetic analysis: a common mutation, R179X. | 2001 |
|
Possible implications of arginase and diamine oxidase in prostatic carcinoma. | 2001 |
|
Ophthalmologic heterogeneity in subjects with gyrate atrophy of choroid and retina harboring the L402P mutation of ornithine aminotransferase. | 2001 Apr |
|
Derivatization and chromatographic behavior of the o-phthaldialdehyde amino acid derivatives obtained with various SH-group-containing additives. | 2001 Apr 13 |
|
Is hyperprolinemia type I actually a benign trait? Report of a case with severe neurologic involvement and vigabatrin intolerance. | 2001 Aug |
|
N(delta)-(5-hydroxy-4,6-dimethylpyrimidine-2-yl)-l-ornithine, a novel methylglyoxal-arginine modification in beer. | 2001 Jan |
|
Medical and surgical therapy of the cystine stone patient. | 2001 Jul |
|
Abnormal elution behavior of ornitine derivatized with 1-fluoro-2,4-dinitrophenyl-5-leucinamide in advanced Marfey's method. | 2001 Jul 6 |
|
Experimental chronic arthritis and granulomatous inflammation induced by bifidobacterium cell walls. | 2001 Jul-Aug |
|
Methohexital affects neutrophil (PMN) dynamic free amino acid pool and immune functions in vitro. | 2001 Jun |
|
Involvement of a transformylase enzyme in siderophore synthesis in Pseudomonas aeruginosa. | 2001 Jun |
|
Occupational lead exposure and amino acid profiles and liver function tests in industrial workers. | 2001 Jun |
|
Arginase I expression and activity in human mononuclear cells after injury. | 2001 Mar |
|
Gastrectomized patients are in a state of chronic protein malnutrition analyses of 23 amino acids. | 2001 Mar-Apr |
|
Nitric oxide modulates cardiac performance in the heart of Anguilla anguilla. | 2001 May |
Patents
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15576628
Measurement of Ca2+-dependent chloride currents in Xenopus laevis oocytes facilitated the deorphanization of human family C G-protein-coupled receptor hGPRC6A/homologous goldfish 5.24 receptor chimeric construct (h6A/5.24) and identification of L-amino acids as agonists. The most active agonists were L-Arg, L-Lys, and L-ornithine, suggesting that these may function as endogenous signaling molecules (only L-Arg, L-Lys, and L-ornithine were able to activate h6A/5.24 at 10 uM concentration).
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
DSLD |
4334 (Number of products:33)
Created by
admin on Fri Dec 15 21:17:48 GMT 2023 , Edited by admin on Fri Dec 15 21:17:48 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID30883964
Created by
admin on Fri Dec 15 21:17:48 GMT 2023 , Edited by admin on Fri Dec 15 21:17:48 GMT 2023
|
PRIMARY | |||
|
3230-94-2
Created by
admin on Fri Dec 15 21:17:48 GMT 2023 , Edited by admin on Fri Dec 15 21:17:48 GMT 2023
|
PRIMARY | |||
|
C002939
Created by
admin on Fri Dec 15 21:17:48 GMT 2023 , Edited by admin on Fri Dec 15 21:17:48 GMT 2023
|
PRIMARY | |||
|
JA08T3B97O
Created by
admin on Fri Dec 15 21:17:48 GMT 2023 , Edited by admin on Fri Dec 15 21:17:48 GMT 2023
|
PRIMARY | |||
|
18599
Created by
admin on Fri Dec 15 21:17:48 GMT 2023 , Edited by admin on Fri Dec 15 21:17:48 GMT 2023
|
PRIMARY | |||
|
32541
Created by
admin on Fri Dec 15 21:17:48 GMT 2023 , Edited by admin on Fri Dec 15 21:17:48 GMT 2023
|
PRIMARY | RxNorm | ||
|
SUB14714MIG
Created by
admin on Fri Dec 15 21:17:48 GMT 2023 , Edited by admin on Fri Dec 15 21:17:48 GMT 2023
|
PRIMARY | |||
|
m8239
Created by
admin on Fri Dec 15 21:17:48 GMT 2023 , Edited by admin on Fri Dec 15 21:17:48 GMT 2023
|
PRIMARY | Merck Index | ||
|
DBSALT002898
Created by
admin on Fri Dec 15 21:17:48 GMT 2023 , Edited by admin on Fri Dec 15 21:17:48 GMT 2023
|
PRIMARY | |||
|
221-772-7
Created by
admin on Fri Dec 15 21:17:48 GMT 2023 , Edited by admin on Fri Dec 15 21:17:48 GMT 2023
|
PRIMARY | |||
|
100000080065
Created by
admin on Fri Dec 15 21:17:48 GMT 2023 , Edited by admin on Fri Dec 15 21:17:48 GMT 2023
|
PRIMARY | |||
|
SUB127311
Created by
admin on Fri Dec 15 21:17:48 GMT 2023 , Edited by admin on Fri Dec 15 21:17:48 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD